EUCTR2005-002738-36-NL进行中（未招募）不适用
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1 Males greater than 18 years of age
- •2 Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate
- •3 Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy (after discontinuation of anti-androgen therapy) as determined by one of the following:
- •Progressive measurable disease on CT scan or MRI as assessed using RECIST guidelines.
- •Progressive non-measurable disease as defined by the appearance of one or more new lesions on bone scan.
- •PSA progression, as defined by two consecutive rising PSA values obtained at least 2 weeks apart, and both obtained at least 4 weeks after the discontinuation of any other anti-androgen therapy. The second PSA value must be = 5.0 ng/mL.
- •4 Detectable metastases by bone scan, CT scan or MRI
- •5 Testosterone < 50 ng/dL (1.73 nmol/L). Must have had orchiectomy or is currently receiving an LHRH agonist/antagonist
- •6 WBC = 3,000 cells/mm3, ANC > 1,500 cells/mm3, hemoglobin = 9 g/dL (5.6 mmol/L), and platelets = 100,000 cells/mm3
- •7 Serum creatinine < 2.0 mg/dL (177 µmol/L)
- •8 Total or direct bilirubin = the upper limit of normal
- •9 AST or ALT = 1.5 times the upper limit of normal concomitant with alkaline phosphatase = 2.5 times the upper limit of normal
- •10 CD4+ lymphocytes > 200 cells/mm³
- •11 ECOG performance status 0-2
- •12 Life expectancy of at least 6 months
- •13 If sexually active, willing to use barrier contraception while on study drug treatment
- •14 The ability to understand and the willingness to sign a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
- •2 Patients taking any Level 3 (opioid) pain medication at any dose with any frequency are excluded from the study. Patients taking Level 2 (moderate) pain medication who are experiencing cancer related pain are not eligible for the study.
- •3 Clinical evidence of brain metastases or history of brain metastases
- •4 Third space fluid accumulation, such as ascites or symptomatic pleural effusion
- •5 Clinically significant active infection or uncontrolled medical condition considered high-risk for docetaxel, corticosteroids or investigational new drug treatment
- •6 Prior gene therapy
- •7 Prior chemotherapy or cancer vaccine for prostate cancer. Chemotherapy is defined as taxanes, mitoxantrone, estramustine, etoposide, vinca alkaloids, cyclophosphamide and anthracyclines.
- •8 Radiation therapy within 4 weeks of randomization. Prior radiation must have been to less than 30% of the bone marrow and patient has recovered from all side effects. Prior use of samarium is acceptable; patients cannot have received strontium.
- •9 Surgery within 4 weeks of randomization. Must have recovered from all side effects.
- •10 Flutamide (Eulexin) within 4 weeks of randomization
- •11 Finesteride (Proscar), bicalutamide (Casodex), nilutamide (androne), within 6 weeks of randomization
- •12 Biologic therapy within 4 weeks of randomization
- •13 Systemic corticosteroid use within 4 weeks of randomization
- •14 History of myocardial infarction or cerebrovascular accident (CVA) within 6 months of randomization
- •15 Thrombotic event requiring anti-coagulation therapy within 4 weeks of randomization
- •16 History of autoimmune disease such as systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis that was previously treated with cytotoxic agents or systemic steroids
- •17 History of another malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years
- •18 Known hypersensitivity to GM-CSF or to any other components of CG1940 and CG8711, which include fetal bovine serum (FBS), DMSO and pentastarch and may include small amounts of dextran sulfate, porcine trypsin and DNase
- •19 Known hypersensitivity to prednisone
- •20 Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80
- •21 Previously randomized in this study, but never received any study drug
研究者
相似试验
已完成
3 期
A Phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic CancerPatients with Locally Advanced or Metastatic Pancreatic CancerJPRN-jRCT2080223564anoCarrier Co., Ltd.310
已完成
3 期
An Open-Label Randomized Phase III Study of Capecitabine(6 months) versus Capecitabine(12 months) as Adjuvant Chemotherapy for Stage III(Dukes'C) Colon Cancer Patients.Colon cancerJPRN-UMIN000001367Japanese Foundation for Multidisciplinary Treatment of Cancer1,200
进行中（未招募）
1 期
Open- Label Randomized Study Comparing Efficacy and Safety of ATV/RTV+3TC with ATV/RTV+TDF/FTC in HIV- Infected, Treatment Naïve Subjects, Followed by Treatment with ATV/RTV+3TCHIVMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2011-006187-47-DKBristol-Myers Squibb International Corporation420
招募中
3 期
Patients with Breast Cancer Previously Treated withEndocrine TherapyCTRI/2022/04/042242Eli Lilly and Company India Pvt Ltd
进行中（未招募）
1 期
A study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)EUCTR2017-004699-77-CZJanssen-Cilag International NV200